Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Veru enrolls first patient in phase 2 clinical trial of VERU-100 » 08:32
06/10/21
06/10
08:32
06/10/21
08:32
VERU

Veru

$9.01 /

-0.03 (-0.33%)

Veru announced that it…

Veru announced that it has enrolled the first patient in its Phase 2 clinical trial of VERU-100, a novel, proprietary gonadotropin-releasing hormone antagonist decapeptide, three-month subcutaneous depot injection formulation, for the treatment of hormone sensitive advanced prostate cancer. The Phase 2 clinical trial is an open label, multicenter, dose finding study evaluating the efficacy and safety of subcutaneous injected doses of VERU-100 in 35 men with hormone sensitive advanced prostate cancer. The primary efficacy endpoint is percent of men that reach castrate levels of total testosterone by Day 28 and maintain castrate testosterone levels beyond 90 days. The secondary endpoint is the percent of men that reach less than 20 ng/dL of total testosterone levels by Day 28 that are maintained at less than 20 ng/dL through Day 91.

ShowHide Related Items >><<
VERU Veru
$9.01 /

-0.03 (-0.33%)

VERU Veru
$9.01 /

-0.03 (-0.33%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$9.01 /

-0.03 (-0.33%)

  • 18
    Feb
VERU Veru
$9.01 /

-0.03 (-0.33%)

VERU Veru
$9.01 /

-0.03 (-0.33%)

Hot Stocks
Veru announces Phase 2 clinical data of enobosarm » 08:43
06/07/21
06/07
08:43
06/07/21
08:43
VERU

Veru

$8.72 /

-0.11 (-1.25%)

Veru announced additional…

Veru announced additional clinical results from the Phase 2 study demonstrating that the anticancer benefits of enobosarm, a selective androgen receptor (AR) targeting agent, were related to the presence and amount of AR expression in breast cancer tissue in subjects with AR+ER+ HER2- metastatic breast cancer, will be presented at the American Society of Clinical Oncology 2021 Annual Meeting being held June 4-8, 2021. Highlights of presentation: In preclinical studies, AR has been established as a tumor suppressor in breast cancer. Clinically, AR is expressed in up to 90% of breast cancers and targeting AR with enobosarm, an oral selective AR agonist, would be a major new endocrine therapy for metastatic breast cancer. The positive G200802 Phase 2 clinical study in 136 heavily pretreated women with AR+ER+HER2- metastatic breast cancer who progressed following CDK4/6 inhibitor and/or estrogen blocking agent treatment confirmed that the AR is commonly expressed in breast cancer tissue and when activated by enobosarm is acting in these patients as a tumor suppressor. In the overall Phase 2 study, the presence and the amount of AR receptor expression in breast cancer tissue correlated with a beneficial antitumor response. The best overall target lesion reduction of greater than30% occurred only in subjects who were AR+. In a post-hoc analysis of 84 women who had AR+ER+HER2- metastatic breast cancer, measurable disease, and centrally confirmed AR status at study entry, an AR positivity threshold of greater than or equal to 40% in breast cancer tissue distinguished patients that responded to enobosarm in both dose arms. AR positivity greater than or equal to 40% was common as 52% of subjects in study met this threshold. Focusing on the 9mg cohort, the dose selected for the Phase 3 ARTEST study, the best objective tumor response rate was 48% for greater than or equal to 40% AR positivity versus 0% for less than40% AR positivity. Similarly, the clinical benefit rate was 79% for greater than or equal to 40% AR positivity versus 18% for less than40% AR positivity. The median radiographic progression free survival was 5.5 month for greater than or equal to 40% AR positivity versus 2.75 months for less than40% AR positivity. Enobosarm was very well tolerated without masculinizing side effects, increases in hematocrit, or liver toxicity. Conclusions from Phase 2 study: Enobosarm, a selective AR agonist, targets AR, a tumor suppressor, in AR+ ER+ HER2- metastatic breast cancer; Objective tumor responses to enobosarm monotherapy require the presence and a threshold level of AR expression in heavily pretreated AR+ ER+ HER2- metastatic breast cancer; AR may be used as a biomarker to identify patients with AR+ ER+ HER2- metastatic breast cancer that are most likely to respond to enobosarm; Enobosarm treatment was well tolerated as an endocrine therapy without masculinizing side effects, increases in hematocrit, or liver toxicity; Targeting the AR tumor suppressor pathway to be studied prospectively in a 3rd line metastatic setting in the Phase 3 ARTEST registration clinical trial of enobosarm monotherapy versus active control for the treatment of AR+ER+HER2- metastatic breast cancer patients who have failed a nonsteroidal aromatase inhibitor, fulvestrant, and a CDK4/6 inhibitor.

ShowHide Related Items >><<
VERU Veru
$8.72 /

-0.11 (-1.25%)

VERU Veru
$8.72 /

-0.11 (-1.25%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$8.72 /

-0.11 (-1.25%)

  • 18
    Feb
VERU Veru
$8.72 /

-0.11 (-1.25%)

VERU Veru
$8.72 /

-0.11 (-1.25%)

Hot Stocks
Veru: Sabizabulin showed evidence of antitumor efficacy in Phase 1b/2 study » 08:24
06/07/21
06/07
08:24
06/07/21
08:24
VERU

Veru

$8.72 /

-0.11 (-1.25%)

Veru announced the…

Veru announced the presentation of the Phase 1b/2 clinical trial update of sabizabulin, an oral cytoskeleton disruptor which in prostate cancer also disrupts androgen receptor transport, to treat men with metastatic castration resistant prostate cancer who failed at least one androgen receptor targeting agent, at the American Society of Clinical Oncology 2021 Annual Meeting being held June 4-8, 2021. The Phase 1b/2 clinical study was designed as a dynamic study with an initial 3+3 standard safety study component followed by an expanded study with increases in dose and schedule. The Phase 1b/2 clinical trial enrolled 80 men and is ongoing with patients in both the Phase 1b and 2 components still on study. Highlights of the study presentation are as follows: Sabizabulin oral daily dosing was well tolerated, and the most common adverse events, being mostly Grade 1 and 2, were diarrhea, fatigue, nausea, and decrease in appetite. There was no evidence of clinically relevant neutropenia or neurotoxicity. Safety profile was similar to that reported in package inserts for androgen receptor targeting agents, abiraterone and enzalutamide. Clinically meaningful and durable evidence of objective tumor responses were observed in patients on 63mg oral daily dosing schedule: In the ITT population with measurable disease, the ORR was 20.7%.

ShowHide Related Items >><<
VERU Veru
$8.72 /

-0.11 (-1.25%)

VERU Veru
$8.72 /

-0.11 (-1.25%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$8.72 /

-0.11 (-1.25%)

  • 18
    Feb
VERU Veru
$8.72 /

-0.11 (-1.25%)

VERU Veru
$8.72 /

-0.11 (-1.25%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
06/04/21
06/04
04:55
06/04/21
04:55
VERU

Veru

$8.84 /

-0.29 (-3.18%)

, CABA

Cabaletta Bio

$10.20 /

-0.05 (-0.49%)

, ICLR

Icon

$220.43 /

-0.04 (-0.02%)

, PRTA

Prothena

$28.65 /

+0.48 (+1.70%)

, SHC

Sotera Health

$24.47 /

+0.04 (+0.16%)

, PHAT

Phathom Pharmaceuticals

$33.20 /

+0.41 (+1.25%)

, CCCC

C4 Therapeutics

$38.13 /

+0.2 (+0.53%)

, LABP

Landos Biopharma

$11.81 /

+0.53 (+4.70%)

, TWST

Twist Bioscience

$96.05 /

-6.22 (-6.08%)

, LVTX

Lava Therapeutics

$11.04 /

+0.05 (+0.45%)

, ACRS

Aclaris Therapeutics

$21.93 /

+0.28 (+1.29%)

, CRSP

Crispr Therapeutics

$109.92 /

-4.79 (-4.18%)

, GILD

Gilead

$66.48 /

+0.44 (+0.67%)

, A

Agilent

$136.40 /

-0.175 (-0.13%)

, ICAD

iCAD

$17.10 /

+0.38 (+2.27%)

, CRIS

Curis

$14.46 /

+0.02 (+0.14%)

, ADUS

Addus HomeCare

$94.40 /

-0.53 (-0.56%)

, VOR

Vor Biopharma

$19.95 /

+0.4 (+2.05%)

, VCNX

Vaccinex

$2.33 /

-0.14 (-5.67%)

2021 Global Healthcare…

2021 Global Healthcare Virtual Conference to be held on June 1-4.

ShowHide Related Items >><<
VOR Vor Biopharma
$19.95 /

+0.4 (+2.05%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

PRTA Prothena
$28.65 /

+0.48 (+1.70%)

PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

ICLR Icon
$220.43 /

-0.04 (-0.02%)

ICAD iCAD
$17.10 /

+0.38 (+2.27%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

CCCC C4 Therapeutics
$38.13 /

+0.2 (+0.53%)

CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

A Agilent
$136.40 /

-0.175 (-0.13%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
ICLR Icon
$220.43 /

-0.04 (-0.02%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
PRTA Prothena
$28.65 /

+0.48 (+1.70%)

06/01/21 Oppenheimer
Prothena price target raised to $45 from $40 at Oppenheimer
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Citi
Prothena initiated with a Buy at Citi
05/12/21 Oppenheimer
Prothena price target raised to $40 from $35 at Oppenheimer
SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

05/14/21 Barclays
Sotera Health price target lowered to $29 from $35 at Barclays
05/14/21 Citi
Sotera Health selloff brings attractive entry point, says Citi
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
CCCC C4 Therapeutics
$38.13 /

+0.2 (+0.53%)

03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

05/11/21 Piper Sandler
Twist Bioscience recent weakness a buying opportunity, says Piper Sandler
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

04/19/21 SVB Leerink
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Leerink
Lava Therapeutics initiated with an Outperform at SVB Leerink
ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
GILD Gilead
$66.48 /

+0.44 (+0.67%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
A Agilent
$136.40 /

-0.175 (-0.13%)

05/26/21 SVB Leerink
Agilent price target raised to $145 from $140 at SVB Leerink
05/26/21 KeyBanc
Agilent price target raised to $157 from $148 at KeyBanc
05/26/21 Wells Fargo
Agilent price target raised to $150 from $140 at Wells Fargo
05/26/21 Baird
Agilent price target raised to $144 from $137 at Baird
ICAD iCAD
$17.10 /

+0.38 (+2.27%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
CRIS Curis
$14.46 /

+0.02 (+0.14%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

08/12/20 BMO Capital
Addus HomeCare price target raised to $115 from $103 at BMO Capital
08/11/20 Oppenheimer
Addus HomeCare price target raised to $115 from $107 at Oppenheimer
06/17/20 Baird
Addus HomeCare price target raised to $100 from $96 at Baird
VOR Vor Biopharma
$19.95 /

+0.4 (+2.05%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

09/25/20 Oppenheimer
Vaccinex price target lowered to $7 from $22 at Oppenheimer
09/22/20 BTIG
Vaccinex downgraded to Neutral from Buy at BTIG
VOR Vor Biopharma
$19.95 /

+0.4 (+2.05%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

PRTA Prothena
$28.65 /

+0.48 (+1.70%)

PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

ICLR Icon
$220.43 /

-0.04 (-0.02%)

ICAD iCAD
$17.10 /

+0.38 (+2.27%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

A Agilent
$136.40 /

-0.175 (-0.13%)

  • 24
    Mar
  • 25
    Mar
  • 18
    Mar
  • 03
    Mar
  • 18
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 17
    Dec
  • 09
    Dec
  • 08
    Dec
  • 03
    Dec
  • 20
    Nov
  • 02
    Oct
  • 13
    Aug
  • 01
    Jul
ICLR Icon
$220.43 /

-0.04 (-0.02%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

PRTA Prothena
$28.65 /

+0.48 (+1.70%)

PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

ICLR Icon
$220.43 /

-0.04 (-0.02%)

ICAD iCAD
$17.10 /

+0.38 (+2.27%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

A Agilent
$136.40 /

-0.175 (-0.13%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

CCCC C4 Therapeutics
$38.13 /

+0.2 (+0.53%)

CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

A Agilent
$136.40 /

-0.175 (-0.13%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
06/03/21
06/03
04:55
06/03/21
04:55
VERU

Veru

$9.12 /

+0.25 (+2.82%)

, CABA

Cabaletta Bio

$10.29 /

-0.77 (-6.96%)

, ICLR

Icon

$220.53 /

-2.16 (-0.97%)

, PRTA

Prothena

$28.17 /

+0.83 (+3.04%)

, SHC

Sotera Health

$24.44 /

+0.13 (+0.53%)

, PHAT

Phathom Pharmaceuticals

$32.70 /

-3.57 (-9.84%)

, CCCC

C4 Therapeutics

$38.02 /

+0.51 (+1.36%)

, LABP

Landos Biopharma

$11.32 /

+0.22 (+1.98%)

, TWST

Twist Bioscience

$102.42 /

-3.45 (-3.26%)

, LVTX

Lava Therapeutics

$10.90 /

-0.12 (-1.09%)

, ACRS

Aclaris Therapeutics

$21.76 /

-1.88 (-7.95%)

, CRSP

Crispr Therapeutics

$114.73 /

-1.02 (-0.88%)

, GILD

Gilead

$66.04 /

+0.73 (+1.12%)

, A

Agilent

$136.58 /

-0.665 (-0.48%)

, ICAD

iCAD

$16.72 /

+0.09 (+0.54%)

, CRIS

Curis

$14.44 /

+0.01 (+0.07%)

, ADUS

Addus HomeCare

$95.26 /

+0.1 (+0.11%)

, VOR

Vor Biopharma

$19.72 /

-0.8 (-3.90%)

, VCNX

Vaccinex

$2.47 /

+0.03 (+1.23%)

2021 Global Healthcare…

2021 Global Healthcare Virtual Conference to be held on June 1-4.

ShowHide Related Items >><<
VOR Vor Biopharma
$19.72 /

-0.8 (-3.90%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

PRTA Prothena
$28.17 /

+0.83 (+3.04%)

PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

ICLR Icon
$220.53 /

-2.16 (-0.97%)

ICAD iCAD
$16.72 /

+0.09 (+0.54%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

CCCC C4 Therapeutics
$38.02 /

+0.51 (+1.36%)

CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

A Agilent
$136.58 /

-0.665 (-0.48%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
ICLR Icon
$220.53 /

-2.16 (-0.97%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
PRTA Prothena
$28.17 /

+0.83 (+3.04%)

06/01/21 Oppenheimer
Prothena price target raised to $45 from $40 at Oppenheimer
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Citi
Prothena initiated with a Buy at Citi
05/12/21 Oppenheimer
Prothena price target raised to $40 from $35 at Oppenheimer
SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

05/14/21 Barclays
Sotera Health price target lowered to $29 from $35 at Barclays
05/14/21 Citi
Sotera Health selloff brings attractive entry point, says Citi
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
CCCC C4 Therapeutics
$38.02 /

+0.51 (+1.36%)

03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

05/11/21 Piper Sandler
Twist Bioscience recent weakness a buying opportunity, says Piper Sandler
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

04/19/21 SVB Leerink
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Leerink
Lava Therapeutics initiated with an Outperform at SVB Leerink
ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
GILD Gilead
$66.04 /

+0.73 (+1.12%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
A Agilent
$136.58 /

-0.665 (-0.48%)

05/26/21 SVB Leerink
Agilent price target raised to $145 from $140 at SVB Leerink
05/26/21 KeyBanc
Agilent price target raised to $157 from $148 at KeyBanc
05/26/21 Wells Fargo
Agilent price target raised to $150 from $140 at Wells Fargo
05/26/21 Baird
Agilent price target raised to $144 from $137 at Baird
ICAD iCAD
$16.72 /

+0.09 (+0.54%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
CRIS Curis
$14.44 /

+0.01 (+0.07%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

08/12/20 BMO Capital
Addus HomeCare price target raised to $115 from $103 at BMO Capital
08/11/20 Oppenheimer
Addus HomeCare price target raised to $115 from $107 at Oppenheimer
06/17/20 Baird
Addus HomeCare price target raised to $100 from $96 at Baird
VOR Vor Biopharma
$19.72 /

-0.8 (-3.90%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

09/25/20 Oppenheimer
Vaccinex price target lowered to $7 from $22 at Oppenheimer
09/22/20 BTIG
Vaccinex downgraded to Neutral from Buy at BTIG
VOR Vor Biopharma
$19.72 /

-0.8 (-3.90%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

PRTA Prothena
$28.17 /

+0.83 (+3.04%)

PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

ICLR Icon
$220.53 /

-2.16 (-0.97%)

ICAD iCAD
$16.72 /

+0.09 (+0.54%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

A Agilent
$136.58 /

-0.665 (-0.48%)

  • 24
    Mar
  • 25
    Mar
  • 18
    Mar
  • 03
    Mar
  • 18
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 17
    Dec
  • 09
    Dec
  • 08
    Dec
  • 03
    Dec
  • 20
    Nov
  • 02
    Oct
  • 13
    Aug
  • 01
    Jul
  • 04
    Jun
ICLR Icon
$220.53 /

-2.16 (-0.97%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

PRTA Prothena
$28.17 /

+0.83 (+3.04%)

PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

ICLR Icon
$220.53 /

-2.16 (-0.97%)

ICAD iCAD
$16.72 /

+0.09 (+0.54%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

A Agilent
$136.58 /

-0.665 (-0.48%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

CCCC C4 Therapeutics
$38.02 /

+0.51 (+1.36%)

CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

A Agilent
$136.58 /

-0.665 (-0.48%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
06/02/21
06/02
04:55
06/02/21
04:55
VERU

Veru

$8.87 /

+0.035 (+0.40%)

, CABA

Cabaletta Bio

$11.06 /

-0.34 (-2.98%)

, ICLR

Icon

$222.66 /

-1.23 (-0.55%)

, PRTA

Prothena

$27.44 /

-1.75 (-6.00%)

, SHC

Sotera Health

$24.31 /

+0.19 (+0.79%)

, PHAT

Phathom Pharmaceuticals

$35.93 /

+0.755 (+2.15%)

, CCCC

C4 Therapeutics

$37.38 /

+0.57 (+1.55%)

, LABP

Landos Biopharma

$11.10 /

+0.1 (+0.91%)

, TWST

Twist Bioscience

$105.85 /

-1.56 (-1.45%)

, LVTX

Lava Therapeutics

$11.00 /

-0.28 (-2.48%)

, ACRS

Aclaris Therapeutics

$23.64 /

+1.37 (+6.15%)

, CRSP

Crispr Therapeutics

$115.72 /

-2.52 (-2.13%)

, GILD

Gilead

$65.31 /

-0.8 (-1.21%)

, A

Agilent

$137.24 /

-0.9 (-0.65%)

, ICAD

iCAD

$16.64 /

+0.18 (+1.09%)

, CRIS

Curis

$14.43 /

+0.05 (+0.35%)

, ADUS

Addus HomeCare

$95.64 /

-0.51 (-0.53%)

, VOR

Vor Biopharma

$20.25 /

-0.68 (-3.25%)

, VCNX

Vaccinex

$2.44 /

+0.08 (+3.39%)

2021 Global Healthcare…

2021 Global Healthcare Virtual Conference to be held on June 1-4.

ShowHide Related Items >><<
VOR Vor Biopharma
$20.25 /

-0.68 (-3.25%)

VERU Veru
$8.87 /

+0.035 (+0.40%)

VCNX Vaccinex
$2.44 /

+0.08 (+3.39%)

TWST Twist Bioscience
$105.85 /

-1.56 (-1.45%)

SHC Sotera Health
$24.31 /

+0.19 (+0.79%)

PRTA Prothena
$27.44 /

-1.75 (-6.00%)

PHAT Phathom Pharmaceuticals
$35.93 /

+0.755 (+2.15%)

LVTX Lava Therapeutics
$11.00 /

-0.28 (-2.48%)

LABP Landos Biopharma
$11.10 /

+0.1 (+0.91%)

ICLR Icon
$222.66 /

-1.23 (-0.55%)

ICAD iCAD
$16.64 /

+0.18 (+1.09%)

GILD Gilead
$65.31 /

-0.8 (-1.21%)

CRSP Crispr Therapeutics
$115.72 /

-2.52 (-2.13%)

CRIS Curis
$14.43 /

+0.05 (+0.35%)

CCCC C4 Therapeutics
$37.38 /

+0.57 (+1.55%)

CABA Cabaletta Bio
$11.06 /

-0.34 (-2.98%)

ADUS Addus HomeCare
$95.64 /

-0.51 (-0.53%)

ACRS Aclaris Therapeutics
$23.64 /

+1.37 (+6.15%)

A Agilent
$137.24 /

-0.9 (-0.65%)

VERU Veru
$8.87 /

+0.035 (+0.40%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
CABA Cabaletta Bio
$11.06 /

-0.34 (-2.98%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
ICLR Icon
$222.66 /

-1.23 (-0.55%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
PRTA Prothena
$27.44 /

-1.75 (-6.00%)

06/01/21 Oppenheimer
Prothena price target raised to $45 from $40 at Oppenheimer
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Citi
Prothena initiated with a Buy at Citi
05/12/21 Oppenheimer
Prothena price target raised to $40 from $35 at Oppenheimer
SHC Sotera Health
$24.31 /

+0.19 (+0.79%)

05/14/21 Barclays
Sotera Health price target lowered to $29 from $35 at Barclays
05/14/21 Citi
Sotera Health selloff brings attractive entry point, says Citi
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
PHAT Phathom Pharmaceuticals
$35.93 /

+0.755 (+2.15%)

05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
CCCC C4 Therapeutics
$37.38 /

+0.57 (+1.55%)

03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
LABP Landos Biopharma
$11.10 /

+0.1 (+0.91%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
TWST Twist Bioscience
$105.85 /

-1.56 (-1.45%)

05/11/21 Piper Sandler
Twist Bioscience recent weakness a buying opportunity, says Piper Sandler
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
LVTX Lava Therapeutics
$11.00 /

-0.28 (-2.48%)

04/19/21 SVB Leerink
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Leerink
Lava Therapeutics initiated with an Outperform at SVB Leerink
ACRS Aclaris Therapeutics
$23.64 /

+1.37 (+6.15%)

04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
CRSP Crispr Therapeutics
$115.72 /

-2.52 (-2.13%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
GILD Gilead
$65.31 /

-0.8 (-1.21%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
A Agilent
$137.24 /

-0.9 (-0.65%)

05/26/21 SVB Leerink
Agilent price target raised to $145 from $140 at SVB Leerink
05/26/21 KeyBanc
Agilent price target raised to $157 from $148 at KeyBanc
05/26/21 Wells Fargo
Agilent price target raised to $150 from $140 at Wells Fargo
05/26/21 Baird
Agilent price target raised to $144 from $137 at Baird
ICAD iCAD
$16.64 /

+0.18 (+1.09%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
CRIS Curis
$14.43 /

+0.05 (+0.35%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
ADUS Addus HomeCare
$95.64 /

-0.51 (-0.53%)

08/12/20 BMO Capital
Addus HomeCare price target raised to $115 from $103 at BMO Capital
08/11/20 Oppenheimer
Addus HomeCare price target raised to $115 from $107 at Oppenheimer
06/17/20 Baird
Addus HomeCare price target raised to $100 from $96 at Baird
VOR Vor Biopharma
$20.25 /

-0.68 (-3.25%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
VCNX Vaccinex
$2.44 /

+0.08 (+3.39%)

09/25/20 Oppenheimer
Vaccinex price target lowered to $7 from $22 at Oppenheimer
09/22/20 BTIG
Vaccinex downgraded to Neutral from Buy at BTIG
VOR Vor Biopharma
$20.25 /

-0.68 (-3.25%)

VERU Veru
$8.87 /

+0.035 (+0.40%)

VCNX Vaccinex
$2.44 /

+0.08 (+3.39%)

TWST Twist Bioscience
$105.85 /

-1.56 (-1.45%)

SHC Sotera Health
$24.31 /

+0.19 (+0.79%)

PRTA Prothena
$27.44 /

-1.75 (-6.00%)

PHAT Phathom Pharmaceuticals
$35.93 /

+0.755 (+2.15%)

LVTX Lava Therapeutics
$11.00 /

-0.28 (-2.48%)

LABP Landos Biopharma
$11.10 /

+0.1 (+0.91%)

ICLR Icon
$222.66 /

-1.23 (-0.55%)

ICAD iCAD
$16.64 /

+0.18 (+1.09%)

GILD Gilead
$65.31 /

-0.8 (-1.21%)

CRSP Crispr Therapeutics
$115.72 /

-2.52 (-2.13%)

CRIS Curis
$14.43 /

+0.05 (+0.35%)

CABA Cabaletta Bio
$11.06 /

-0.34 (-2.98%)

ADUS Addus HomeCare
$95.64 /

-0.51 (-0.53%)

ACRS Aclaris Therapeutics
$23.64 /

+1.37 (+6.15%)

A Agilent
$137.24 /

-0.9 (-0.65%)

  • 24
    Mar
  • 25
    Mar
  • 18
    Mar
  • 03
    Mar
  • 18
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 17
    Dec
  • 09
    Dec
  • 08
    Dec
  • 03
    Dec
  • 20
    Nov
  • 02
    Oct
  • 13
    Aug
  • 01
    Jul
  • 04
    Jun
ICLR Icon
$222.66 /

-1.23 (-0.55%)

GILD Gilead
$65.31 /

-0.8 (-1.21%)

VERU Veru
$8.87 /

+0.035 (+0.40%)

TWST Twist Bioscience
$105.85 /

-1.56 (-1.45%)

PRTA Prothena
$27.44 /

-1.75 (-6.00%)

PHAT Phathom Pharmaceuticals
$35.93 /

+0.755 (+2.15%)

LVTX Lava Therapeutics
$11.00 /

-0.28 (-2.48%)

LABP Landos Biopharma
$11.10 /

+0.1 (+0.91%)

ICLR Icon
$222.66 /

-1.23 (-0.55%)

ICAD iCAD
$16.64 /

+0.18 (+1.09%)

GILD Gilead
$65.31 /

-0.8 (-1.21%)

CRSP Crispr Therapeutics
$115.72 /

-2.52 (-2.13%)

CRIS Curis
$14.43 /

+0.05 (+0.35%)

ADUS Addus HomeCare
$95.64 /

-0.51 (-0.53%)

ACRS Aclaris Therapeutics
$23.64 /

+1.37 (+6.15%)

A Agilent
$137.24 /

-0.9 (-0.65%)

VERU Veru
$8.87 /

+0.035 (+0.40%)

VCNX Vaccinex
$2.44 /

+0.08 (+3.39%)

SHC Sotera Health
$24.31 /

+0.19 (+0.79%)

GILD Gilead
$65.31 /

-0.8 (-1.21%)

CRSP Crispr Therapeutics
$115.72 /

-2.52 (-2.13%)

CRIS Curis
$14.43 /

+0.05 (+0.35%)

CCCC C4 Therapeutics
$37.38 /

+0.57 (+1.55%)

CABA Cabaletta Bio
$11.06 /

-0.34 (-2.98%)

A Agilent
$137.24 /

-0.9 (-0.65%)

Conference/Events
Jefferies to hold a virtual conference » 10:03
06/01/21
06/01
10:03
06/01/21
10:03
VERU

Veru

$8.91 /

+0.075 (+0.85%)

, CABA

Cabaletta Bio

$11.34 /

-0.06 (-0.53%)

, ICLR

Icon

$221.66 /

-2.23 (-1.00%)

, PRTA

Prothena

$29.10 /

-0.09 (-0.31%)

, SHC

Sotera Health

$24.10 /

-0.02 (-0.08%)

, PHAT

Phathom Pharmaceuticals

$35.33 /

+0.155 (+0.44%)

, CCCC

C4 Therapeutics

$37.59 /

+0.78 (+2.12%)

, LABP

Landos Biopharma

$10.99 /

-0.01 (-0.09%)

, TWST

Twist Bioscience

$108.01 /

+0.6 (+0.56%)

, LVTX

Lava Therapeutics

$11.28 /

+ (+0.00%)

, ACRS

Aclaris Therapeutics

$22.70 /

+0.43 (+1.93%)

, CRSP

Crispr Therapeutics

$118.32 /

+0.08 (+0.07%)

, GILD

Gilead

$66.02 /

-0.09 (-0.14%)

, A

Agilent

$137.87 /

-0.27 (-0.20%)

, ICAD

iCAD

$16.47 /

+0.01 (+0.06%)

, CRIS

Curis

$14.85 /

+0.47 (+3.27%)

, ADUS

Addus HomeCare

$96.15 /

+ (+0.00%)

, VOR

Vor Biopharma

$21.37 /

+0.44 (+2.10%)

, VCNX

Vaccinex

$2.36 /

+ (+0.00%)

2021 Global Healthcare…

2021 Global Healthcare Virtual Conference to be held on June 1-4.

ShowHide Related Items >><<
VOR Vor Biopharma
$21.37 /

+0.44 (+2.10%)

VERU Veru
$8.91 /

+0.075 (+0.85%)

VCNX Vaccinex
$2.36 /

+ (+0.00%)

TWST Twist Bioscience
$108.01 /

+0.6 (+0.56%)

SHC Sotera Health
$24.10 /

-0.02 (-0.08%)

PRTA Prothena
$29.10 /

-0.09 (-0.31%)

PHAT Phathom Pharmaceuticals
$35.33 /

+0.155 (+0.44%)

LVTX Lava Therapeutics
$11.28 /

+ (+0.00%)

LABP Landos Biopharma
$10.99 /

-0.01 (-0.09%)

ICLR Icon
$221.66 /

-2.23 (-1.00%)

ICAD iCAD
$16.47 /

+0.01 (+0.06%)

GILD Gilead
$66.02 /

-0.09 (-0.14%)

CRSP Crispr Therapeutics
$118.32 /

+0.08 (+0.07%)

CRIS Curis
$14.85 /

+0.47 (+3.27%)

CCCC C4 Therapeutics
$37.59 /

+0.78 (+2.12%)

CABA Cabaletta Bio
$11.34 /

-0.06 (-0.53%)

ADUS Addus HomeCare
$96.15 /

+ (+0.00%)

ACRS Aclaris Therapeutics
$22.70 /

+0.43 (+1.93%)

A Agilent
$137.87 /

-0.27 (-0.20%)

VERU Veru
$8.91 /

+0.075 (+0.85%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
CABA Cabaletta Bio
$11.34 /

-0.06 (-0.53%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
ICLR Icon
$221.66 /

-2.23 (-1.00%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
PRTA Prothena
$29.10 /

-0.09 (-0.31%)

06/01/21 Oppenheimer
Prothena price target raised to $45 from $40 at Oppenheimer
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Citi
Prothena initiated with a Buy at Citi
05/12/21 Oppenheimer
Prothena price target raised to $40 from $35 at Oppenheimer
SHC Sotera Health
$24.10 /

-0.02 (-0.08%)

05/14/21 Barclays
Sotera Health price target lowered to $29 from $35 at Barclays
05/14/21 Citi
Sotera Health selloff brings attractive entry point, says Citi
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
PHAT Phathom Pharmaceuticals
$35.33 /

+0.155 (+0.44%)

05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
CCCC C4 Therapeutics
$37.59 /

+0.78 (+2.12%)

03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
LABP Landos Biopharma
$10.99 /

-0.01 (-0.09%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
TWST Twist Bioscience
$108.01 /

+0.6 (+0.56%)

05/11/21 Piper Sandler
Twist Bioscience recent weakness a buying opportunity, says Piper Sandler
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
LVTX Lava Therapeutics
$11.28 /

+ (+0.00%)

04/19/21 SVB Leerink
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Leerink
Lava Therapeutics initiated with an Outperform at SVB Leerink
ACRS Aclaris Therapeutics
$22.70 /

+0.43 (+1.93%)

04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
CRSP Crispr Therapeutics
$118.32 /

+0.08 (+0.07%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
GILD Gilead
$66.02 /

-0.09 (-0.14%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
A Agilent
$137.87 /

-0.27 (-0.20%)

05/26/21 SVB Leerink
Agilent price target raised to $145 from $140 at SVB Leerink
05/26/21 KeyBanc
Agilent price target raised to $157 from $148 at KeyBanc
05/26/21 Wells Fargo
Agilent price target raised to $150 from $140 at Wells Fargo
05/26/21 Baird
Agilent price target raised to $144 from $137 at Baird
ICAD iCAD
$16.47 /

+0.01 (+0.06%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
CRIS Curis
$14.85 /

+0.47 (+3.27%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
ADUS Addus HomeCare
$96.15 /

+ (+0.00%)

08/12/20 BMO Capital
Addus HomeCare price target raised to $115 from $103 at BMO Capital
08/11/20 Oppenheimer
Addus HomeCare price target raised to $115 from $107 at Oppenheimer
06/17/20 Baird
Addus HomeCare price target raised to $100 from $96 at Baird
VOR Vor Biopharma
$21.37 /

+0.44 (+2.10%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
VCNX Vaccinex
$2.36 /

+ (+0.00%)

09/25/20 Oppenheimer
Vaccinex price target lowered to $7 from $22 at Oppenheimer
09/22/20 BTIG
Vaccinex downgraded to Neutral from Buy at BTIG
VOR Vor Biopharma
$21.37 /

+0.44 (+2.10%)

VERU Veru
$8.91 /

+0.075 (+0.85%)

VCNX Vaccinex
$2.36 /

+ (+0.00%)

TWST Twist Bioscience
$108.01 /

+0.6 (+0.56%)

SHC Sotera Health
$24.10 /

-0.02 (-0.08%)

PRTA Prothena
$29.10 /

-0.09 (-0.31%)

PHAT Phathom Pharmaceuticals
$35.33 /

+0.155 (+0.44%)

LVTX Lava Therapeutics
$11.28 /

+ (+0.00%)

LABP Landos Biopharma
$10.99 /

-0.01 (-0.09%)

ICLR Icon
$221.66 /

-2.23 (-1.00%)

ICAD iCAD
$16.47 /

+0.01 (+0.06%)

GILD Gilead
$66.02 /

-0.09 (-0.14%)

CRSP Crispr Therapeutics
$118.32 /

+0.08 (+0.07%)

CRIS Curis
$14.85 /

+0.47 (+3.27%)

CABA Cabaletta Bio
$11.34 /

-0.06 (-0.53%)

ADUS Addus HomeCare
$96.15 /

+ (+0.00%)

ACRS Aclaris Therapeutics
$22.70 /

+0.43 (+1.93%)

A Agilent
$137.87 /

-0.27 (-0.20%)

  • 24
    Mar
  • 25
    Mar
  • 18
    Mar
  • 03
    Mar
  • 18
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 17
    Dec
  • 09
    Dec
  • 08
    Dec
  • 03
    Dec
  • 20
    Nov
  • 02
    Oct
  • 13
    Aug
  • 01
    Jul
  • 04
    Jun
ICLR Icon
$221.66 /

-2.23 (-1.00%)

GILD Gilead
$66.02 /

-0.09 (-0.14%)

VERU Veru
$8.91 /

+0.075 (+0.85%)

TWST Twist Bioscience
$108.01 /

+0.6 (+0.56%)

PRTA Prothena
$29.10 /

-0.09 (-0.31%)

PHAT Phathom Pharmaceuticals
$35.33 /

+0.155 (+0.44%)

LVTX Lava Therapeutics
$11.28 /

+ (+0.00%)

LABP Landos Biopharma
$10.99 /

-0.01 (-0.09%)

ICLR Icon
$221.66 /

-2.23 (-1.00%)

ICAD iCAD
$16.47 /

+0.01 (+0.06%)

GILD Gilead
$66.02 /

-0.09 (-0.14%)

CRSP Crispr Therapeutics
$118.32 /

+0.08 (+0.07%)

CRIS Curis
$14.85 /

+0.47 (+3.27%)

ADUS Addus HomeCare
$96.15 /

+ (+0.00%)

ACRS Aclaris Therapeutics
$22.70 /

+0.43 (+1.93%)

A Agilent
$137.87 /

-0.27 (-0.20%)

VERU Veru
$8.91 /

+0.075 (+0.85%)

VCNX Vaccinex
$2.36 /

+ (+0.00%)

SHC Sotera Health
$24.10 /

-0.02 (-0.08%)

GILD Gilead
$66.02 /

-0.09 (-0.14%)

CRSP Crispr Therapeutics
$118.32 /

+0.08 (+0.07%)

CRIS Curis
$14.85 /

+0.47 (+3.27%)

CCCC C4 Therapeutics
$37.59 /

+0.78 (+2.12%)

CABA Cabaletta Bio
$11.34 /

-0.06 (-0.53%)

A Agilent
$137.87 /

-0.27 (-0.20%)

Over a month ago
Hot Stocks
Veru enrolls first patient in Phase 3 trial of sabizabulin » 08:40
05/19/21
05/19
08:40
05/19/21
08:40
VERU

Veru

$8.01 /

+0.23 (+2.96%)

Veru announced that it…

Veru announced that it has enrolled the first patient in its Phase 3 clinical trial of sabizabulin, a novel, proprietary, oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties, to combat the effects of COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2.

ShowHide Related Items >><<
VERU Veru
$8.01 /

+0.23 (+2.96%)

VERU Veru
$8.01 /

+0.23 (+2.96%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$8.01 /

+0.23 (+2.96%)

  • 18
    Feb
VERU Veru
$8.01 /

+0.23 (+2.96%)

VERU Veru
$8.01 /

+0.23 (+2.96%)

Earnings
Veru reports Q2 EPS (4c), consensus (4c) » 06:39
05/12/21
05/12
06:39
05/12/21
06:39
VERU

Veru

$7.50 /

+0.1 (+1.35%)

Reports Q2 revenue…

Reports Q2 revenue $13.3M, consensus $14.29M. "We reported another great quarter largely based on all-time record high quarterly FC2 net revenues from the U.S. prescription channel," said CEO Mitchell Steiner. "We also will be enrolling our first patient in our Phase 3 clinical trial of sabizabulin in high risk hospitalized COVID-19 patients this week. Because of sabizabulin's anti-inflammatory and anti-viral properties and its favorable safety profile, we think sabizabulin could be that desperately needed oral therapeutic to prevent deaths in hospitalized patients with moderate to severe COVID-19 disease who are at risk for Acute Respiratory Distress Syndrome. COVID-19 remains a serious threat worldwide and effective treatments are desperately needed. We are advancing our novel oral drug candidates for the treatment of prostate and breast advanced cancers. We plan this month to enroll our first patient in the Phase 3 VERACITY clinical trial of sabizabulin for metastatic castration and androgen receptor targeting agent resistant prostate cancer. We plan to also enroll this month our first patient in the Phase 2 clinical trial of VERU-100, a novel long-acting GnRH antagonist injection formulation for androgen deprivation therapy. Next month, the Phase 3 ARTEST enobosarm for 3rd line AR+ER+ metastatic breast cancer is also expected to start enrolling. We are now a solid late clinical stage oncology biopharmaceutical company with novel drug candidates in development."

ShowHide Related Items >><<
VERU Veru
$7.50 /

+0.1 (+1.35%)

VERU Veru
$7.50 /

+0.1 (+1.35%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VERU Veru
$7.50 /

+0.1 (+1.35%)

  • 18
    Feb
VERU Veru
$7.50 /

+0.1 (+1.35%)

VERU Veru
$7.50 /

+0.1 (+1.35%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:35
05/05/21
05/05
12:35
05/05/21
12:35
GM

General Motors

$57.72 /

+2.38 (+4.30%)

, LYFT

Lyft

$54.03 /

-2.14 (-3.81%)

, PTON

Peloton

$85.35 /

-11.52 (-11.89%)

, HNST

Honest Company

$23.00 /

+1.7 (+7.98%)

, PFE

Pfizer

$40.84 /

+0.865 (+2.16%)

, BNTX

BioNTech

$193.73 /

+16.83 (+9.51%)

, TMUS

T-Mobile

$134.60 /

+5.89 (+4.58%)

, FB

Facebook

$319.01 /

+0.405 (+0.13%)

, ATNX

Athenex

$5.22 /

+1.5 (+40.32%)

, VERU

Veru

$8.76 /

+0.04 (+0.46%)

, ESPR

Esperion

$19.40 /

-6.19 (-24.19%)

, HFC

HollyFrontier

$33.72 /

-2.54 (-7.00%)

, RDS.A

Royal Dutch Shell

$39.75 /

+1.11 (+2.87%)

, RDS.B

Royal Dutch Shell

$37.42 /

+1.21 (+3.34%)

The major averages are…

ShowHide Related Items >><<
VERU Veru
$8.76 /

+0.04 (+0.46%)

TMUS T-Mobile
$134.60 /

+5.89 (+4.58%)

RDS.B Royal Dutch Shell
$37.42 /

+1.21 (+3.34%)

RDS.A Royal Dutch Shell
$39.75 /

+1.11 (+2.87%)

PTON Peloton
$85.35 /

-11.52 (-11.89%)

PFE Pfizer
$40.84 /

+0.865 (+2.16%)

LYFT Lyft
$54.03 /

-2.14 (-3.81%)

HFC HollyFrontier
$33.72 /

-2.54 (-7.00%)

GM General Motors
$57.72 /

+2.38 (+4.30%)

FB Facebook
$319.01 /

+0.405 (+0.13%)

ESPR Esperion
$19.40 /

-6.19 (-24.19%)

BNTX BioNTech
$193.73 /

+16.83 (+9.51%)

ATNX Athenex
$5.22 /

+1.5 (+40.32%)

GM General Motors
$57.72 /

+2.38 (+4.30%)

04/22/21 Wolfe Research
Wolfe upgrades Ford with $15 target, sees GM-like 'significant re-rating'
04/20/21 BofA
Lordstown Motors initiated with a Neutral at BofA
04/14/21 Evercore ISI
General Motors price target raised to $65 from $62 at Evercore ISI
04/05/21
Fly Intel: Top five analyst initiations
LYFT Lyft
$54.03 /

-2.14 (-3.81%)

05/05/21 DA Davidson
Lyft price target raised to $72 from $66 at DA Davidson
05/05/21 Susquehanna
Lyft ridesharing recovery taking place, says Susquehanna
05/05/21 Morgan Stanley
Lyft price target raised to $70 from $65 at Morgan Stanley
05/05/21 Stifel
Lyft price target raised to $60 from $55 at Stifel
PTON Peloton
$85.35 /

-11.52 (-11.89%)

05/05/21 Truist
Peloton recall likely to result in one time financial costs, says Truist
05/05/21 KeyBanc
Peloton Tread, Tread+ recalls a 'clear negative,' says KeyBanc
04/19/21 JPMorgan
Peloton should be bought on pullback from safety warning, says JPMorgan
04/19/21 Truist
CSPC warning unlikely to have material impact on Peloton P&L, saysTruist
HNST Honest Company
$23.00 /

+1.7 (+7.98%)

PFE Pfizer
$40.84 /

+0.865 (+2.16%)

05/05/21 JPMorgan
Pfizer price target raised to $40 from $36 at JPMorgan
05/05/21 Barclays
Pfizer price target raised to $40 from $37 at Barclays
04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
BNTX BioNTech
$193.73 /

+16.83 (+9.51%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
TMUS T-Mobile
$134.60 /

+5.89 (+4.58%)

04/26/21 Oppenheimer
Crown Castle price target raised to $205 from $170 at Oppenheimer
04/19/21 Deutsche Bank
T-Mobile price target raised to $185 from $155 at Deutsche Bank
03/30/21 KeyBanc
KeyBanc sees partnership with Google as neutral to T-Mobile
03/12/21 Morgan Stanley
T-Mobile highlighted 'impressive' cash flow ramp at event, says Morgan Stanley
FB Facebook
$319.01 /

+0.405 (+0.13%)

04/29/21 KeyBanc
Facebook price target raised to $414 from $360 at KeyBanc
04/29/21 Truist
Facebook price target raised to $400 from $350 at Truist
04/29/21 Wedbush
Facebook price target raised to $355 from $340 at Wedbush
04/29/21 Canaccord
Facebook price target raised to $380 from $350 at Canaccord
ATNX Athenex
$5.22 /

+1.5 (+40.32%)

03/02/21
Fly Intel: Top five analyst downgrades
03/02/21 SVB Leerink
Athenex downgraded to Market Perform from Outperform at SVB Leerink
03/02/21 Oppenheimer
Athenex downgraded to Perform from Outperform at Oppenheimer
03/02/21 Truist
Athenex downgraded to Hold from Buy at Truist
VERU Veru
$8.76 /

+0.04 (+0.46%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
ESPR Esperion
$19.40 /

-6.19 (-24.19%)

05/05/21 BTIG
Esperion price target lowered to $71 from $90 at BTIG
05/05/21 Northland
Esperion price target lowered to $24 from $30 at Northland
05/05/21 Credit Suisse
Esperion price target lowered to $36 from $45 at Credit Suisse
05/05/21 Stifel
Stifel downgrades Esperion to Hold with bull case seen 'off the table'
HFC HollyFrontier
$33.72 /

-2.54 (-7.00%)

04/01/21 Piper Sandler
HollyFrontier price target raised to $45 from $35 at Piper Sandler
03/17/21 US Capital Advisors
HollyFrontier downgraded to Hold from Overweight at US Capital Advisors
03/08/21 Barclays
HollyFrontier price target raised to $38 from $35 at Barclays
02/26/21 Mizuho
HollyFrontier price target raised to $40 from $25 at Mizuho
RDS.A Royal Dutch Shell
$39.75 /

+1.11 (+2.87%)

04/30/21 Credit Suisse
Royal Dutch Shell price target raised to 1,860 GBp at Credit Suisse
04/20/21 Deutsche Bank
Royal Dutch Shell initiated with a Buy at Deutsche Bank
04/08/21 Barclays
Royal Dutch Shell price target raised to 1,700 GBp from 1,500 GBp at Barclays
04/01/21 Piper Sandler
Royal Dutch Shell price target raised to $55 from $48 at Piper Sandler
RDS.B Royal Dutch Shell
$37.42 /

+1.21 (+3.34%)

03/12/21 Societe Generale
Royal Dutch Shell upgraded to Buy from Hold at Societe Generale
03/03/21 JPMorgan
Royal Dutch Shell price target raised to 2,000 GBp from 1,700 GBp at JPMorgan
02/12/21 Scotiabank
Royal Dutch Shell upgraded to Sector Perform from Underperform at Scotiabank
VERU Veru
$8.76 /

+0.04 (+0.46%)

TMUS T-Mobile
$134.60 /

+5.89 (+4.58%)

RDS.A Royal Dutch Shell
$39.75 /

+1.11 (+2.87%)

PTON Peloton
$85.35 /

-11.52 (-11.89%)

PFE Pfizer
$40.84 /

+0.865 (+2.16%)

LYFT Lyft
$54.03 /

-2.14 (-3.81%)

HFC HollyFrontier
$33.72 /

-2.54 (-7.00%)

GM General Motors
$57.72 /

+2.38 (+4.30%)

FB Facebook
$319.01 /

+0.405 (+0.13%)

ESPR Esperion
$19.40 /

-6.19 (-24.19%)

ATNX Athenex
$5.22 /

+1.5 (+40.32%)

  • 05
    May
  • 18
    Feb
  • 10
    Sep
  • 23
    Jul
  • 24
    Jun
TMUS T-Mobile
$134.60 /

+5.89 (+4.58%)

RDS.B Royal Dutch Shell
$37.42 /

+1.21 (+3.34%)

RDS.A Royal Dutch Shell
$39.75 /

+1.11 (+2.87%)

PTON Peloton
$85.35 /

-11.52 (-11.89%)

PFE Pfizer
$40.84 /

+0.865 (+2.16%)

LYFT Lyft
$54.03 /

-2.14 (-3.81%)

HNST Honest Company
$23.00 /

+1.7 (+7.98%)

HFC HollyFrontier
$33.72 /

-2.54 (-7.00%)

GM General Motors
$57.72 /

+2.38 (+4.30%)

FB Facebook
$319.01 /

+0.405 (+0.13%)

BNTX BioNTech
$193.73 /

+16.83 (+9.51%)

VERU Veru
$8.76 /

+0.04 (+0.46%)

TMUS T-Mobile
$134.60 /

+5.89 (+4.58%)

PTON Peloton
$85.35 /

-11.52 (-11.89%)

PFE Pfizer
$40.84 /

+0.865 (+2.16%)

LYFT Lyft
$54.03 /

-2.14 (-3.81%)

GM General Motors
$57.72 /

+2.38 (+4.30%)

FB Facebook
$319.01 /

+0.405 (+0.13%)

ESPR Esperion
$19.40 /

-6.19 (-24.19%)

BNTX BioNTech
$193.73 /

+16.83 (+9.51%)

ATNX Athenex
$5.22 /

+1.5 (+40.32%)

VERU Veru
$8.76 /

+0.04 (+0.46%)

TMUS T-Mobile
$134.60 /

+5.89 (+4.58%)

PTON Peloton
$85.35 /

-11.52 (-11.89%)

PFE Pfizer
$40.84 /

+0.865 (+2.16%)

LYFT Lyft
$54.03 /

-2.14 (-3.81%)

HFC HollyFrontier
$33.72 /

-2.54 (-7.00%)

GM General Motors
$57.72 /

+2.38 (+4.30%)

FB Facebook
$319.01 /

+0.405 (+0.13%)

BNTX BioNTech
$193.73 /

+16.83 (+9.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.